AUTHOR=Wang Dong , Gao Min , Zhang Kaihui , Jin Ruifeng , Lv Yuqiang , Liu Yong , Ma Jian , Wan Ya , Gai Zhongtao , Liu Yi 

TITLE=Molecular Genetics Analysis of 70 Chinese Families With Muscular Dystrophy Using Multiplex Ligation-Dependent Probe Amplification and Next-Generation Sequencing

JOURNAL=Frontiers in Pharmacology

VOLUME=10

YEAR=2019

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.00814

DOI=10.3389/fphar.2019.00814

ISSN=1663-9812

ABSTRACT=<p><bold>Background:</bold> Muscular dystrophy (MD) includes multiple types, of which dystrophinopathies caused by <italic>dystrophin</italic> (<italic>DMD</italic>) mutations are the most common types in children. An accurate identification of the causative mutation at the genomic level is critical for genetic counseling of the family, and analysis of genotype–phenotype correlations, as well as a reference for the development of gene therapy.</p><p><bold>Methods:</bold> Totally, 70 Chinese families with suspected MD probands were enrolled in the study. The multiplex ligation-dependent probe amplification (MLPA) was first performed to screen large deletions/duplications of <italic>DMD</italic> exons in the patients, and then, next-generation sequencing (NGS) was carried out to detect small mutations in the MLPA-negative patients.</p><p><bold>Results:</bold> Totally, 62 mutations of <italic>DMD</italic> were found in 62 probands with DMD/BMD, and two compound heterozygous mutations in <italic>LAMA2</italic> were identified in two probands with MDC1A (a type of congenital MD), indicating that the diagnostic yield was 91.4% by MLPA plus NGS for MD diagnosis in this cohort. Out of the mutations, 51 large mutations encompassing 47 (75.8%) deletions and four duplications (6.5%) were identified by MLPA; 11 small mutations including six (9.7%) nonsense, two (3.2%) small deletions, two splice-site mutations (3.2%), and one small insertion (1.6%) were found by NGS. Large mutations were found most frequently in the hotspot region between exons 45 and 55 (70.6%). Out of the 11 patients harboring point mutations in <italic>DMD</italic>, 8 were novel mutations. Additionally, one novel mutation in <italic>LAMA2</italic> was identified. All the novel mutations were analyzed and predicted as pathogenic according to American College of Medical Genetics and Genomics (ACMG) guideline. Finally, 34 DMD, 4 BMD, 24 BMD/DMD, and 2 MDC1A were diagnosed in the cohort.</p><p><bold>Conclusion:</bold> Our data indicated that the MLPA plus NGS can be a comprehensive and effective tool for precision diagnosis and potential treatment of MD and is particularly necessary for the patients at very young age with only two clinical indicators (persistent hyperCKemia and typical myopathy performance on electromyogram) but no definite clinical manifestations.</p>